Short answer: As of April 28, 2026, a Justice Department / DEA final order places FDA-approved drug products containing marijuana and marijuana subject to a qualifying state (or DC) medical marijuana license in Schedule III of the Controlled Substances Act. That is a real federal change for the licensed medical channel. It is not the same thing as Congress creating DC recreational sales, and it does not by itself rewrite ABCA’s patient rules. Broader rescheduling of marijuana as a whole from Schedule I to Schedule III is still a separate, unfinished administrative process.
This explainer states only what primary sources say, with dates. We do not predict the DEA Administrator’s final decision, court outcomes, or tax advice for licensees.
Need to buy legally in DC today? Register first: start your ABCA registration. Licensed stores: DC dispensary directory · dispensary map.
The timeline that matters (dated facts)
| Date | What happened | Source |
|---|---|---|
| Aug 29, 2023 | HHS sent DEA a medical/scientific evaluation recommending marijuana be controlled in Schedule III | Cited in the April 2026 final rule |
| May 21, 2024 | DOJ/DEA published a notice of proposed rulemaking to transfer marijuana to Schedule III | Federal Register, 89 FR 44597 (NPRM; Docket DEA-1362) |
| Dec 18, 2025 | Presidential executive order directed expeditious completion of rescheduling rulemaking | Cited in DOJ April 23, 2026 release |
| Apr 23, 2026 | DOJ announced an order placing FDA-approved marijuana products and marijuana under qualifying state medical licenses in Schedule III, plus a new hearing track for broader rescheduling | DOJ OPA |
| Apr 28, 2026 | Final rule published / effective: Schedule III for FDA-approved products containing marijuana and marijuana subject to a state medical marijuana license; import/export permit rules updated; expedited DEA registration pathway for state licensees | Federal Register (91 FR 22714) |
| Jun 29, 2026 | New administrative hearing began on broader rescheduling under the May 2024 NPRM | Scheduled in the DOJ April 23, 2026 release |
| Sep 29, 2026 | DEA Chief ALJ Derek C. Julius stayed the broader proceeding while he weighs a motion to add a Sept. 23 GAO report on drug-scheduling procedures to the record; government response due Oct. 13 | Stay order |
| Oct 6, 2026 | DEA opened new Form 225 registrations for state medical cannabis manufacturers, distributors and testing labs | Marijuana Moment |
| Oct 9, 2026 | DOJ and challengers to the April order proposed a D.C. Circuit briefing schedule running to Feb. 19, 2027 (subject to court approval) | IgniteIt |
| Oct 13, 2026 | DEA filed its response: it defers to the judge on admitting the GAO report but opposes more briefing. Opponents asked for a narrow reopening for discovery and testimony. The stay stays in place until the judge rules | Marijuana Moment |
KOL framing (updated Oct. 13): there are now two tracks, and neither moves fast this fall. The broad hearing is paused until the judge rules on the GAO motion, and the court fight over the April order is on a briefing schedule that runs into February 2027. For DC, the part that matters already happened: the April order covers marijuana under state medical licenses, and DC's licensed market is medical-only. Track A (done): medical / state-licensed marijuana in Schedule III under the April order. Track B (open): whether all marijuana moves to Schedule III under the 2024 NPRM.
What the April 2026 order does say
From the Federal Register final rule (effective April 28, 2026):
- It places in Schedule III marijuana (as defined in the CSA), marijuana extract, and naturally derived delta-9-THC to the extent they are in an FDA-approved drug product or are subject to a state medical marijuana license (the rule’s definition includes a District of Columbia entity license).
- It keeps unlicensed bulk / non–state-licensed marijuana in Schedule I, in the rule’s own description of how treaty obligations continue to be met.
- It creates an expedited DEA registration path for entities that already hold state medical marijuana licenses.
- It notes tax implications under Internal Revenue Code § 280E for schedule I/II trafficking — and explicitly says the rule is not a determination of any licensee’s tax liability (consult tax counsel).
We are not giving tax, criminal-defense, or banking advice. Licensees should read the rule and their own counsel.
What it does not change for DC patients tomorrow morning
Be blunt — this is the section most rescheduling explainers bury:
- DC is still a medical retail market. Congress’s appropriations rider continues to block District-funded recreational-sales legalization while it remains in force. See our companion analysis: Why DC still doesn’t have recreational sales.
- You still need to be a registered patient or caregiver to buy from ABCA-licensed retailers (ABCA patients). DC residents can follow our DC medical card self-certification guide.
- Public consumption rules don’t flip. Streets, parks, and federal land stay restricted under DC and federal rules (DC Code § 48-911.01; MPD; where you can smoke).
- Unlicensed shops are still unlicensed. Federal scheduling language about state medical licenses does not legalize padlocked or never-licensed storefronts. Use our DC cannabis license lookup to confirm a store.
- Possession limits, purchase limits, and ABCA endorsements (Delivery, Safe-Use, etc.) are still DC/ABCA rules unless ABCA or the Council changes them through their own processes (Council bills are public on DC Council LIMS). See DC possession limits under Initiative 71 and ABCA’s Safe-Use lounge endorsement.
If someone claims “weed is legal recreationally in DC now because of Schedule III,” they are mixing Track A with a sales system DC still does not have.
How this interacts with Congress’s DC rider (CRS, not our prediction)
The annual DC appropriations rider restricts District spending to legalize or reduce penalties for Schedule I substances (and “tetrahydrocannabinols derivative”) for recreational purposes. The Congressional Research Service has analyzed that moving marijuana out of Schedule I could, as a matter of local law, widen what the District may authorize — including commercial recreational sale — while federal controlled-substance law would still exist separately (CRS LSB11188).
CRS also flags the undefined “tetrahydrocannabinols derivative” phrase in the rider as a complication. That is why we refuse to headline “rescheduling kills the rider.” Lawyers will argue; Congress can also rewrite the rider. Patients should watch enacted text, not vibes.
Practical checklist for DC patients
- Buying: still ABCA medical registration → licensed retailer or licensed delivery. Start: medical cannabis registration. Visiting? Visitor rules for buying in DC.
- Finding stores: licensed DC dispensaries · map.
- Lounges: only Active Safe-Use retailers — DC lounges with ABCA Safe-Use endorsements.
- Following federal process: use the Federal Register docket and DOJ/DEA primary releases; treat secondary coverage as a pointer, not the record.
What we are watching next (no forecasts)
- Any ALJ recommended decision or Administrator final rule on the broader May 2024 NPRM.
- Any ABCA patient or licensee guidance that references the April 2026 Schedule III order.
- Any new FSGG rider language in the next District funding vehicle.
When those documents exist, we will update with dates — not speculation.
Sources
- Federal Register NPRM, May 21, 2024 (89 FR 44597; Docket DEA-1362): https://www.federalregister.gov/documents/2024/05/21/2024-11137/schedules-of-controlled-substances-rescheduling-of-marijuana
- DOJ Office of Public Affairs, April 23, 2026: https://www.justice.gov/opa/pr/justice-department-places-fda-approved-marijuana-products-and-products-containing-marijuana
- Federal Register final rule, April 28, 2026 (91 FR 22714): https://www.federalregister.gov/documents/2026/04/28/2026-08176/schedules-of-controlled-substances-rescheduling-of-food-and-drug-administration-approved-products
- CRS LSB11188, Impact of Proposed Rescheduling of Marijuana on D.C. Regulatory Authority: https://www.congress.gov/crs_external_products/LSB/PDF/LSB11188/LSB11188.2.pdf
- ABCA, Medical Cannabis Patients: https://abca.dc.gov/page/medical-cannabis-patients
- DC Code § 48-911.01: https://code.dccouncil.gov/us/dc/council/code/sections/48-911.01
- MPD, Marijuana: https://mpdc.dc.gov/marijuana
- DC Council LIMS: https://lims.dccouncil.gov/
- Companion analysis: “Why DC Still Doesn’t Have Recreational Sales” (DCWeedHub, linked above)
Last updated: October 7, 2026
DCWeedHub is an independent guide to DC’s ABCA-licensed cannabis market. We list ABCA-licensed businesses only and aren’t affiliated with or endorsed by ABCA, DEA, or DOJ. This is general information, not legal, tax, or medical advice. 21+.